Interestingly, blocking only CXCR3 led to a loss of tumor control through this combination therapy, underpinning the importance of Batf3 DCs and CXCR3 ligands for the recruitment of CTLs and tumor killing. The gene discussed is BATF3; the disease is neoplasm.